<article id="moa_2" class="slide" data-ag-slide-name="MOA 2">
    <div class="basic">
      <h1 data-ag-editable="MOA 2 Main Title">Neulasta<sup>®</sup> is eliminated primarily via neutrophils – thus is cleared<br /> only when neutrophil levels are sufficient<sup>1</sup></h1>
      <div class="main_content_style" id="moa_page2_data_holder">
         <h2 data-ag-editable="MOA 2 Graph Title">Neulasta<sup>®</sup> works as needed to restore ANC levels, with a single injection per cycle<sup>2</sup></h2>
         <div id="moa_page2_data_image1" class="image_style"><p data-ag-editable="MOA 2 Left Box Copy">PEGFILGRASTIM</p></div>
         <div id="moa_page2_data_graph_bg">
            <img src="content/images/carer_pages/moa/moa_page2_graph1_bg.png" width="568" height="292" data-ag-editable="MOA 2 Graph Background" />
             <div id="moa_2_graph_content"  data-ag-editable="MOA 2 Graph Content">
                 <p id="graph_vertical_axis_title">Median ANC (Cell x 10<sup>9</sup>/L)<br/> and median Neulasta<sup>®</sup><br/> plasma concentration (ng/mL)</p>
                 <p id="graph_horizontal_axis_title">Day of treatment</p>
                 <p id="graph_bottom_text">Adapted from Mey U, <span class="et_al">et al.</span> 2002</p>
             </div>
            <div id="moa_page2_data_graph_lines">
           	   <img src="content/images/carer_pages/moa/moa_page2_graph1_lines.png" width="418" height="172" data-ag-editable="MOA 2 Graph Lines" />
                <p id="line_1_value" data-ag-editable="MOA 2 Graph Line 1 Value">ANZ</p>
                <p id="line_2_value" data-ag-editable="MOA 2 Graph Line 2 Value">Neulasta<sup>®</sup></p>
            </div>
         </div>
         <div id="moa_page2_data_bottom" data-ag-editable="MOA 2 Graph Bottom Copy"><p><span>✓</span> Patients need only a single injection per cycle<sup>2</sup></p><p><span>✓</span> Neulasta<sup>®</sup> works only as needed<sup>3</sup></p></div>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="moa_2_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="MOA 2 References Title">References:</strong></p>
          <div data-ag-editable="MOA 2 References List">
             <ol>
                <li>Molineux G <em>et al</em>. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patientsAnticancer Drugs 2003; 14(4):259-264</li>
                <li>Mey U <em>et al</em>. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Cancer Care 2007; 15(7):877-884</li>
                <li>Johnston E <em>et al</em>. Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy. J Clin Oncol 2000; 18(13):2522-2528</li>
             </ol>
          </div>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>